Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years

Rosenberger, Albert; Illig, Thomas; Korb, K; Klopp, Norman; Zietemann, Vera; Wölke, Gabriele; Meese, Eckart; Sybrecht, Gerhard W.; Kronenberg, Florian; Cebulla, Matthias; Degen, Maria; Drings, P.; Gröschel, A.; Konietzko, N.; Kreymborg, Karsten grosse; Häußinger, K.; Höffken, G.; Jilge, Bettina; Ko, You-Dschun; Morr, H; Schmidt, Christine; Schmidt, E-Wilhelm; Täuscher, D.; Bickeböller, Heike; Wichmann, H‐Erich

doi:10.1186/1471-2407-8-60

Cited by 53 publications

(35 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This hypothesis has been demonstrated in a few recent studies, looking at the association between early onset lung cancer and genes involved in xenobiotic metabolizing enzymes 24 and DNA repair. 25,26 We are beginning to examine the influence of genetic background in Chinese young lung cancer patients. Compared with squamous cell cancer, more patients with adenocarcinoma harbor mutations of the epidermal growth factor receptor (EGFR), which is highly sensitive to EGFR tyrosine kinase inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Zhang

Chen

Zhen

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The treatment, prognosis, and outcomes of young lung cancer patients have not been fully explored. In addition, there is a pressing need to characterize this subgroup of patients, because there is a trend of increasing incidence in younger patients from Europe and Japan. METHODS: Consecutive, nonselected young patients (<45 years old) with pathologically diagnosed lung cancer treated at 175 qualified hospitals in the greater Shanghai area were included in this analysis. Incidence, prognostic factors, and treatment outcome of lung cancer patients from 2002 to 2006 were documented. A comparison with lung cancer patients of any age was also made. RESULTS: A total of 12,380 patients with nonsmall cell lung cancer were registered. Among them, 652 patients were between 15 and 45 years old. One-year, 3-year, and 5-year survival rates of lung cancer patients younger than 45 years were 49.87%, 26.68%, and 23.12%, respectively. TNM stage, treatment hospital (tertiary vs community hospital), sex, and cancer histology were confirmed as independent prognostic factors. Compared with lung cancer patients of any age in Shanghai, the percentage of adenocarcinoma in the young male subgroup was significantly higher (63.77% vs 43.19%, P < .001). Interestingly, median survival time of young lung cancer patients was similar with that of lung cancer patients of any age, but was significantly shorter than the median survival of middle-aged patients (45-60 years old). CONCLUSIONS: Median survival of the middle-aged group (45-60 years) was significantly longer than the young group (<45 years) and the old group (>60 years). Therefore, aggressive treatment modalities should be strongly considered for young lung cancer patients. Cancer 2010;116;3656-62.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Zhang

Chen

Zhen

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…Thereafter, emerging studies have been done to evaluate the association between GPx-1 Pro198Leu polymorphism and risks for diVerent types of tumor in diverse populations, such as breast cancer (Ravn-Haren et al 2006;Cox et al 2004;Ahn et al 2005;Hu and Diamond 2003;Knight et al 2004;Cebrian et al 2006), lung cancer (Rosenberger et al 2008;Yang et al 2004;Ratnasinghe et al 2000;RaaschouNielsen et al 2007;Skuladottir et al 2005;Lee et al 2006), bladder cancer (Ichimura et al 2004;Paz-y-Mino et al 2010;Reszka et al 2009;Goerlitz et al 2011), prostate cancer (Choi et al 2007;Arsova-SaraWnovska et al 2009;Steinbrecher et al 2010), colorectal cancer Hansen et al 2005Hansen et al , 2009 and other cancers (Rajaraman et al 2008;Bhatti et al 2009;Wang et al 2008;Hu et al 2004;Ezzikouri et al 2010;Lightfoot et al 2006;Wu et al 2010;Tang et al 2010;Vogel et al 2004;He et al 2011). However, the results from those studies remain debatable rather than conclusive.…”

Section: Introductionmentioning

confidence: 99%

GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis

Chen

Cao

Qin

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Zhe Zhang 1 , Xiu-Yue Yu 1 , Guo-Jun Zhang 2 , Kun-Feng Guo 1 , Chui-Ze Kong 1 * may have a potential protective effect on tobacco-related carcinogenesis of lung and UADT cancers (Rosenberger et al, 2008;Li et al, 2011). Various reports have associated genetic polymorphism in mEH with increased risk of ovarian cancer, hepatocellular carcinoma, and other disease syndromes (Pande et al, 2008;Kiran et al, 2009;Goode et al, 2011).…”

Section: Low Microsomal Epoxide Hydrolase Expression Is Associated Wimentioning

confidence: 99%

Low Microsomal Epoxide Hydrolase Expression is Associated with Bladder Carcinogenesis and Recurrence

Zhang

Yu²,

Zhang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Microsomal epoxide hydrolase (mEH) plays a significant role in the metabolism of numerous xenobiotics and is associated with several forms of cancer. Here, we investigated the role of mEH expression in bladder carcinogenesis, subsequent progression and recurrence. The expression of mEH was analyzed by Western blot in 50 bladder urothelial carcinoma and 20 normal epithelial tissues. There was a significantly higher mEH expression in the normal epithelium (P<0.05) and mEH expression was lower in high stage than in low stage tumors (P<0.05). Further, immunohistochmistry in 106 bladder urothelial carcinoma demonstrated mEH expression to be negatively correlated with histological grade, pT stage and recurrence (P<0.05). These findings suggest the important role of mEH in bladder carcinogenesis, cancer development and recurrence, providing support for efforts to develop mEH-based gene therapy.

show abstract

Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years

Abstract: Background: Early onset lung cancer shows some familial aggregation, pointing to a genetic predisposition. This study was set up to investigate the role of candidate genes in the susceptibility to lung cancer patients younger than 51 years at diagnosis.

Cited by 53 publications

References 64 publications

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis

Low Microsomal Epoxide Hydrolase Expression is Associated with Bladder Carcinogenesis and Recurrence

Contact Info

Product

Resources

About